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ABSTRACT Acinetobacter baumannii causes a wide range of nosocomial infections.
This pathogen is considered a threat to human health due to the increasingly fre-
quent isolation of multidrug-resistant strains. There is a major gap in knowledge on
the infection biology of A. baumannii, and only a few virulence factors have been
characterized, including lipopolysaccharide. The lipid A expressed by A. baumannii is
hepta-acylated and contains 2-hydroxylaurate. The late acyltransferases controlling
the acylation of lipid A have been already characterized. Here, we report the charac-
terization of A. baumannii LpxO, which encodes the enzyme responsible for the
2-hydroxylation of lipid A. By genetic methods and mass spectrometry, we demon-
strate that LpxO catalyzes the 2-hydroxylation of the laurate transferred by A. bau-
mannii LpxL. LpxO-dependent lipid A 2-hydroxylation protects A. baumannii from
polymyxin B, colistin, and human -defensin 3. LpxO contributes to the survival of A.
baumannii in human whole blood and is required for pathogen survival in the wax-
moth Galleria mellonella. LpxO also protects Acinetobacter from G. mellonella antimi-
crobial peptides and limits their expression. Further demonstrating the importance
of LpxO-dependent modiﬁcation in immune evasion, 2-hydroxylation of lipid A limits
the activation of the mitogen-activated protein kinase Jun N-terminal protein kinase
to attenuate inﬂammatory responses. In addition, LpxO-controlled lipid A modiﬁca-
tion mediates the production of the anti-inﬂammatory cytokine interleukin-10 (IL-10)
via the activation of the transcriptional factor CREB. IL-10 in turn limits the produc-
tion of inﬂammatory cytokines following A. baumannii infection. Altogether, our
studies suggest that LpxO is a candidate for the development of anti-A. baumannii
drugs.
KEYWORDS Acinetobacter, lipid A, virulence
Lipopolysaccharide (LPS), located in the outer leaﬂet of the outer membrane (OM), iscomposed of three regions: the lipid A moiety, the core oligosaccharide, and the
O-polysaccharide. Hexa-acylated lipid A, such as the canonical lipid A structure ex-
pressed by Escherichia coli K-12 (1), is recognized by the Toll-like receptor 4 (TLR4)-MD2
complex, resulting in the activation of downstream signaling cascades leading to
cytokine production and subsequent inﬂammation (2). The lipid A structure can be
modiﬁed by pathogens in response to different conditions (1, 3). Well-characterized
modiﬁcations are the addition or removal of fatty acids, alteration of the phosphate
groups, or additions of other chemical groups, such as amino acids and sugars (1, 3).
These modiﬁcations may result in resistance to cationic antimicrobial peptides (CAMPs),
reduced or increased activation of inﬂammatory responses, or greater protection
against disturbances in pH or desiccation (2, 3).
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Acinetobacter baumannii is an opportunistic Gram-negative pathogen causing a
wide range of nosocomial infections, although the most common clinical manifesta-
tions comprise ventilator-associated pneumonia and central line-associated blood-
stream infections (4). A. baumannii is considered a global threat to human health due
to the increasing isolation of multidrug-, extensively drug-, and even pan-drug-resistant
strains. Colistin and tigecycline have become the last-line treatment for multidrug-
resistant A. baumannii (5). Despite its clinical relevance, there is a major knowledge gap
on the infection biology of A. baumannii, and only a few virulence factors have been
characterized, including LPS (6). A. baumannii synthesizes lipooligosaccharide (LOS),
rather than LPS, due to the absence of the O-polysaccharide. Structurally, A. baumannii
lipid A consists of a (1=-6)-linked disaccharide of glucosamine phosphorylated at the
1 and 4= positions with positions 2, 3, 2=, and 3= acylated with R-3-hydroxymyristoyl
groups. The 2 and 3= R-3-hydroxymyristoyl groups are further acylated with laurate
(C12) through the action of the late acyltransferase LpxM, whereas the 2’ R-3-
hydroxymyristoyl group is acylated with laurate (C12) through the action of the late
acyltransferase LpxL. Thus, in contrast to many Gram-negative pathogens, lipid A of A.
baumannii is predominantly hepta-acylated (7–11). The evidence demonstrates that
hepta-acylation of A. baumannii lipid A promotes resistance to CAMPs, contributes to
desiccation survival, and is important for A. baumannii virulence (7). This lipid A is
recognized by the TLR4/MD2 receptor complex and triggers the activation of NF-B and
mitogen-activated protein kinases (MAPKs) to induce inﬂammation and antibacterial
molecules such as defensins (7, 8).
A. baumannii can modify its lipid A with phosphoethanolamine and galactosamine,
and these modiﬁcations are implicated in colistin resistance (9–11). PmrC/EptA is
responsible for the addition of phosphoethanolamine to lipid A (9), whereas NaxD is
required for the modiﬁcation with galactosamine (10). The PmrAB two-component
system governs expression of PmrC and NaxD, and there are reports of clinical isolates
harboring mutations in PmrA or PmrB leading to the upregulation of the system with
a concomitant increase in the replacement of the lipid A with phosphoethanolamine
and galactosamine (9–11). Colistin resistance is also mediated through complete loss of
the LOS by loss-of-function mutations within genes essential for lipid A biosynthesis
(lpxA, lpxC, or lpxD) (12). However, LOS-deﬁcient strains of A. baumannii show a
dramatic reduction in virulence, and not all strains possess the ability to mutate
early-stage lipid A biosynthetic enzymes (13).
All of the published studies on A. baumannii lipid A report the presence of
2-hydroxylaurate (7–11). Few Gram-negative bacteria have been shown to produce
lipid A species containing hydroxylated secondary acyl chains, and the evidence
suggests that this lipid A modiﬁcation enables the pathogens to successfully infect their
hosts. In Vibrio cholerae, the late acyltransferase LpxN is responsible for transferring the
hydroxylated laurate to the lipid A domain (14), whereas in Bordetella bronchiseptica,
Salmonella enterica serovar Typhimuirum, and Klebsiella pneumoniae, the incorporation
of a hydroxyl group in a fatty acid is catalyzed by the enzyme LpxO (15–17). Interest-
ingly, in silico analysis of A. baumannii genomes revealed the presence of an lpxO
homolog, suggesting that A. baumannii LpxO is responsible for the lipid A modiﬁcation
with 2-hydroxylaurate. In this work, we characterized A. baumannii lpxO, which is
required for the hydroxylation of lipid A. This study demonstrates that LpxO plays an
important role in A. baumannii infection biology, since LpxO-dependent lipid A mod-
iﬁcation protects the pathogen from CAMPs, mediates resistance to phagocytosis, and
limits the activation of host defense responses in invertebrates and mammalian cells.
RESULTS
A. baumannii LpxO 2-hydroxylates lipid A. In silico analyses of A. baumannii
genomes revealed that this pathogen carries one homolog of K. pneumoniae and S.
enterica serovar Typhimurium lpxO. Analysis of the genome of A. baumannii strain ATCC
17978 showed that LpxO (locus tag A1S_0308) is 62 and 59% identical to K. pneumoniae
and Salmonella enterica serovar Typhimurium LpxO, respectively (Fig. 1A). To conﬁrm
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that the identiﬁed loci are indeed responsible for the 2-hydroxylation of lipid A, A.
baumannii strain ATCC 17978 lpxO was mutated by double recombination. Control
experiments showed that the wild type and lpxO mutant had similar growth kinetics in
both rich and minimal media (see Fig. S1 in the supplemental material). Lipid A was
extracted from the wild type and the lpxO mutant using an ammonium hydroxide-
isobutyric acid method and subjected to negative-ion matrix-assisted laser desorption
ionization–time of ﬂight (MALDI-TOF) mass spectrometry. Lipid A produced by the wild
type contained the species with mass-to-charge ratios (m/z) of 1,910, 1,728, and 1,530
(Fig. 1B). These molecular species have been previously found in lipid A of A. baumannii
strains (7–11), and the proposed chemical structures are shown in Fig. 1E. In contrast,
the lpxO mutant produced a lipid A which contained the species m/z 1,894, 1,712, and
1,514, an m/z difference of 16 compared to the wild-type species (i.e., m/z 1,910, 1,728,
and 1,530, respectively), which corresponded with the lack of ions containing
2-hydroxylaurate (C12:OH) (Fig. 1C). Complementation of the mutant restored the pro-
duction of wild-type lipid A (Fig. 1D), demonstrating that lpxO is responsible for the
2-hydroxylation of A. baumannii lipid A.
We sought to determine whether other membrane lipids were affected in the
membrane of the lpxO mutant. However, the analysis of the lipid composition by
thin-layer chromatography did not reveal any differences in the levels of cardiolipin,
phosphatidylglycerol, or phosphoethanolamine between the membranes of the wild
type and lpxO mutant (Fig. S2A).
To assess whether the changes in the lipid A structure observed in the lpxO mutant
affect the outer membrane permeability to hydrophobic agents, we measured the
FIG 1 A. baumannii LpxO 2-hydroxylates lipid A. (A) A. baumannii encodes an LpxO homolog with 62% and 59% sequence similarity to K. pneumoniae and S.
enterica serovar Typhimurium LpxO, respectively. Shown are negative-ion MALDI-TOF mass spectrometry spectra of lipid A puriﬁed from A. baumannii ATCC
17978 (B), A. baumannii ΔlpxO mutant (ΔlpxO) (C), and A. baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO) (D). Data represent the mass-to-charge ratios (m/z)
of each lipid A species detected and are representative of three extractions. (E) Proposed lipid A structures of the species produced by wild-type A. baumannii
based on previous publications (7–11).
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partition of the hydrophobic ﬂuorescent probe (1-N-phenylnaphthylamine; NPN) into
the cell membrane. NPN is excluded by the intact bacterial OM but exhibits increased
ﬂuorescence after partitioning into disrupted OMs (18). Thus, an increase in ﬂuores-
cence indicates alterations in the OM. However, we did not observe any differences in
the uptake of NPN between the wild type and the lpxO mutant (Fig. S2B), suggesting
that no major functional alterations occur in the OM of the lpxO mutant.
A. baumannii LpxO hydroxylates the laurate linked to the 2’ R-3-hydroxymyristoyl
group of lipid A. Recently, Boll and coworkers (7) have shown that 2-hydroxylation in
A. baumannii lipid A is absent from an lpxLAb mutant, suggesting that LpxO hydroxy-
lates the 2’-R-hydroxylaurate group. To validate this hypothesis, we used a genetic
approach by expressing LpxO in E. coli BN1 (19). This E. coli strain produces the
canonical hexa-acylated lipid A of m/z 1,797 (Fig. 2A), corresponding to a (1=-6)-linked
disaccharide of glucosamine phosphorylated at the 1 and 4= positions, with positions
2, 3, 2=, and 3= being acylated with R-3-hydroxymyristoyl groups. The 2= and 3=
R-3-hydroxymyristoyl groups are further acylated with laurate (C12) and myristate (C14)
(19). Expression of A. baumannii LpxO in E. coli BN1 resulted in the hydroxylation of the
hexa-acylated lipid A species to give m/z 1,813 (Fig. 2B). In contrast, LpxO-mediated
2-hydroxylation was not observed when LpxO was expressed in the E. coli BN1 lpxL
mutant (Fig. 2C), conﬁrming that LpxO hydroxylates the laurate fatty acid chain
transferred by LpxL.
LpxO-dependent lipid A modiﬁcation increases A. baumannii resistance to anti-
microbial peptides. Polymyxins B and E (also known as colistin) interact with LPS by
electrostatic interactions, causing a disruption of the OM barrier (20, 21). Polymyxin B
is most often used as a topical ointment, whereas colistin is becoming the antibiotic of
last resort to treat multidrug-resistant infections, including those triggered by A.
baumannii. We sought to determine whether LpxO-dependent lipid A modiﬁcation
protects A. baumannii from polymyxins. Results displayed in Fig. 3 demonstrate that the
lpxO mutant was more susceptible than the wild type to both polymyxin B and colistin.
Complementation restored wild-type levels of resistance, suggesting that LpxO-
dependent hydroxylation contributes to A. baumannii resistance to polymyxins.
FIG 2 A. baumannii LpxO modiﬁes the LpxL-transferred lauryl group. Shown are negative-ion MALDI-TOF
mass spectrometry spectra of lipid A puriﬁed from E. coli BN1 (A), E. coli BN1::Tn7lpxO mutant (BN1::
Tn7lpxO) (B), and E. coli BN1-ΔlpxL::Tn7lpxO mutant (BN1- ΔlpxL::Tn7lpxO) (C). Data represent the m/z of
each lipid A species detected and are representative of three extractions.
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Human antimicrobial peptides such as defensins are weapons of the innate immune
system against infections. They do share with polymyxins the initial interaction with the
LPS (20), and we therefore hypothesized that LpxO-mediated lipid A modiﬁcation
increases resistance to human antimicrobial peptides. To test this hypothesis, we
exposed A. baumannii strains to -defensin 3 and determined the survival after 1 h of
incubation. Human -defensin 3 is active against multidrug-resistant bacteria, and it
has been reported to increase severalfold in the lungs upon infection (22–24). We
observed increased killing of the lpxO mutant by -defensin 3 (Fig. 3C). The enhanced
killing was abrogated in the complemented strain, indicating that LpxO-mediated lipid
A modiﬁcation is associated with resistance to -defensin 3.
Altogether, our ﬁndings demonstrate that LpxO-governed 2-hydroxylation of A.
baumannii lipid A promotes resistance to human antimicrobial peptides and clinically
relevant polymyxins.
LpxO contributes to survival of A. baumannii in human whole blood. Bacterial
killing assays in whole blood allow the ex vivo assessment of the interaction between
pathogens and professional phagocytes. We then sought to determine whether LpxO
contributes to A. baumannii survival in whole human blood. The lpxO mutant was
recovered in signiﬁcantly lower numbers than the wild type (Fig. 4), whereas there were
not differences between the complemented and wild-type strains. These results dem-
FIG 3 Deletion of lpxO decreases A. baumannii resistance to CAMPs. Shown is percent survival of A.
baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO mutant
(ΔlpxO::Tn7lpxO) following 1 h of exposure to polymyxin B (A), colistin (B), and human -defensin 3 (C).
Values are presented as the means  standard deviations (SD) from three independent experiments
measured in duplicate. P values were 0.01 (***) and 0.001 (****) for the indicated comparisons using
one-way ANOVA with Bonferroni contrasts; n.s., not signiﬁcant.
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onstrate that the decreased survival of the lpxO mutant in whole human blood is
associated with the lack of 2-hydroxylation in lipid A.
A. baumannii lpxO is attenuated in the Galleria mellonella infection model. The
G. mellonella infection model is widely used to assess the virulence of A. baumannii (25).
Moreover, there is good correlation between virulence in G. mellonella and that in the
mouse model (26, 27). Equal numbers of CFU of all three strains were injected into G.
mellonella, and survival of the larvae was monitored over several days. Inoculation with
sterile PBS into the larvae resulted in no mortality (Fig. 5). Three days postinoculation,
only 10% of the Galleria organisms survived when challenged with the wild-type and
complemented strains; in contrast, 50% of the larvae survived when inoculated with the
lpxO mutant (Fig. 5).
CAMPs are part of the G. mellonella defenses activated upon infection (28). A few
hours after infection, multiple CAMPs are synthesized and released into the hemolymph
to neutralize bacterial infection (28–30). Therefore, we sought to determine whether
the lpxO mutant is susceptible to these antimicrobial peptides. G. mellonella was
challenged with heatkilled Escherichia coli to boost the expression of antimicrobial
peptides (29, 30), and after 24 h, the hemolymph rich in CAMPs was collected and used
to assess the susceptibility of the A. baumannii strains by a broth microdilution assay.
Results shown in Fig. 5B demonstrate that the lpxO mutant was more susceptible to G.
mellonella peptides than the wild type. Complementation restored the wild-type levels
of resistance to the hemolymph peptides, indicating that the 2-hydroxylation of A.
baumannii lipid A promotes resistance to a repertoire of CAMPs produced in response
to infections.
We have previously demonstrated that there is a correlation between virulence of
Gram-negative pathogens and the expression of G. mellonella antimicrobial peptides
(29, 30). The reduced virulence of the lpxO mutant led us to assess the expression of
CAMPs in G. mellonella larvae infected with the lpxO mutant. After 12 h of infection, the
expression levels of gallerimycin, galiomycin, and lysozyme were signiﬁcantly higher in
larvae infected with the lpxO mutant than in larvae infected with the wild-type strain
(Fig. 5C to E). Complementation restored the expression of the peptides to wild-type
levels, suggesting that the 2-hydroxylation of A. baumannii lipid A is associated with an
attenuated expression of G. mellonella CAMPs.
Altogether, our ﬁndings provide evidence that LpxO-mediated 2-hydroxylation of A.
baumannii lipid A is necessary for the virulence of this pathogen in G. mellonella by
limiting the production of CAMPs and promoting resistance to them.
FIG 4 Deletion of lpxO increases human phagocyte-mediated killing of A. baumannii. Three hundred l
of fresh human blood (from three different donors) was mixed with 1 107 CFU of A. baumannii ATCC
17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO)
and incubated at 37°C for 3 h. The bacterial counts recovered were then divided by the initial counts.
Experiments were performed with duplicate samples on three independent occasions. *, P 0.05 versus
A. baumannii ATCC 17978, determined using one-way ANOVA with Bonferroni contrasts; n.s., not
signiﬁcant.
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Hydroxylated A. baumannii lipid A reduces inﬂammatory responses in macro-
phages. The lipid A pattern is recognized by the TLR4/MD2 complex, leading to the
activation of innate signaling pathways and resulting in inﬂammation and clearance of
the infection. However, many pathogens alter the LPS molecular pattern to evade
detection by the TLR4/MD2 complex to reduce inﬂammation (2). Therefore, we sought
FIG 5 A. baumannii lpxO mutant displays decreased virulence in the G. mellonella waxworm infection
model. (A) Percent survival of G. mellonella over 72 h postinfection with 5 104 organisms of A.
baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO mutant
(ΔlpxO::Tn7lpxO). Thirty larvae were infected in each group. Level of signiﬁcance was determined using
the log-rank (Mantel-Cox) test with Bonferroni correction for multiple comparisons. (B) Percent survival
of A. baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO
mutant (ΔlpxO::Tn7lpxO) following 1 h of exposure to G. mellonella hemolymph obtained from larvae
challenged with heat-killed E. coli. (C to E) G. mellonella antimicrobial peptide expression determined
after 12 h of infection with A. baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A.
baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO) by reverse transcriptase quantitative realtime PCR.
Three larvae per group were infected, and values are presented as the means  SD from two
independent cDNA preparations measured in duplicate. In panels B to E, P values were 0.05 (*), 0.01
(**),0.001 (***), and0.0001 (****) versus A. baumannii ATCC 17978, determined using one-way ANOVA
with Bonferroni contrasts.
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to investigate whether LpxO-dependent lipid A modiﬁcation helps A. baumannii to limit
the activation of inﬂammatory responses. Figure 6A shows that the expression of tnf
was higher in immortalized bone marrow-derived macrophages (iBMDMs) infected with
the lpxO mutant than in iBMDMs infected with the wild type. As anticipated, the lpxO
mutant induced higher levels of tumor necrosis factor alpha (TNF-) than the wild type
(Fig. 6B). Complementation restored the expression and production of cytokines to
wild-type levels, indicating that the heightened inﬂammation induced by the lpxO
mutant is due to the lack of 2-hydroxylation in lipid A.
The activation of NF-B and MAPK governed inﬂammatory responses following
infection. We then sought to determine the signaling pathways activated by the lpxO
mutant. iBMDMs were infected with the wild type, the lpxO mutant, and the comple-
mented strain, with the activation of NFB and MAPKs assessed by immunoblotting. In
the canonical NFB activation pathway, nuclear translocation of NFB is preceded by
phosphorylation and subsequent degradation of IB. All strains triggered the degra-
dation of IB (Fig. 6C), and no differences were observed between strains. Whereas
FIG 6 lpxO deletion in A. baumannii results in upregulation of inﬂammatory responses in macrophages
upon infection. (A) tnf expression in iBMDMs infected for 5 h with UV-killed A. baumannii ATCC 17978,
A. baumannii ΔlpxOmutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxOmutant (ΔlpxO::Tn7lpxO) by reverse
transcriptase quantitative realtime PCR. Values are presented as the means  SD from three indepen-
dent cDNA preparations measured in duplicate. (B) TNF- secretion by iBMDMs stimulated for 5 h with
UV-killed A. baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::
Tn7lpxO mutant (ΔlpxO::Tn7lpxO). In panels A and B, P values were 0.05 (*) and 0.0001 (****) versus
A. baumannii ATCC 17978, determined using one-way ANOVA with Bonferroni contrasts. (C) Immunoblot
analysis of IB and tubulin levels in lysates of iBMDMs infected with UV-killed A. baumannii ATCC 17978,
A. baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO) for the
indicated times. (D) Immunoblot analysis of phosphoJNK (pJNK), phosphoERK (pERK), phosphor-p38
(pp38), and tubulin levels in lysates of iBMDMs infected with UV-killed A. baumannii ATCC 17978, A.
baumannii ΔlpxO mutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO). In panels C
and D, data are representative of at least three independent experiments.
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the three strains triggered the phosphorylation of the MAPKs p38, extracellular signal-
regulated kinase (ERK), and Jun N-terminal protein kinase (JNK) (Fig. 6B), the phosphor-
ylation of JNK was increased in macrophages infected with the lpxO mutant. Image
analysis showed a 22 and 281% increase in the phosphorylation of JNK 20 and 40 min
postinfection with the lpxO mutant, respectively, compared to the phosphorylation
induced by the wild type. The complemented strain induced phosphorylation of JNK
similar to that of the wild type at all time points. Control experiments showed that A.
baumannii induction of TNF- is dependent on the activation of JNK, because the levels
of this cytokine were signiﬁcantly lower in the supernatants of infected macrophages
treated with the JNK inhibitor SP600125 (Fig. S3). Collectively, these results indicate that
the 2-hydroxylation of lipid A limits the activation of MAPK JNK to attenuate inﬂam-
matory responses.
Interestingly, the expression of the anti-inﬂammatory cytokine il10 was signiﬁcantly
reduced in iBMDMs infected with the lpxO mutant, whereas we did not observe any
difference in il10 levels triggered by the wild-type and complemented strains (Fig. 7A).
These results suggested that the 2-hydroxylation of A. baumannii lipid A contributes to
FIG 7 lpxO deletion in A. baumannii results in a decrease in il10 expression. (A) il10 expression in iBMDMs
infected for 5 h with UV-killed A. baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A.
baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO) by reverse transcriptase quantitative realtime PCR.
Values are presented as the means  SD from three independent cDNA preparations measured in
duplicate. (B) tnf expression in il10/ iBMDMs infected for 5 h with UV-killed A. baumannii ATCC 17978,
A. baumannii ΔlpxOmutant (ΔlpxO), and A. baumannii ΔlpxO::Tn7lpxOmutant (ΔlpxO::Tn7lpxO) by reverse
transcriptase quantitative realtime PCR. Values are presented as the means SD from two independent
cDNA preparations measured in duplicate. (C) il10 expression in control (AS) and CREB siRNA-transfected
iBMDMs infected for 5 h with UV-killed A. baumannii ATCC 17978 by reverse transcriptase quantitative
realtime PCR. Values are presented as the means  SD from two independent cDNA preparations
measured in duplicate. (D) Immunoblot analysis of phosphor-CREB (pCREB) and tubulin levels in lysates
of iBMDMs infected with UV-killed A. baumannii ATCC 17978, A. baumannii ΔlpxO mutant (ΔlpxO), and A.
baumannii ΔlpxO::Tn7lpxO mutant (ΔlpxO::Tn7lpxO). Data are representative of at least three indepen-
dent experiments. In panels A to C, P values were0.05 (*) and 0.0001 (****) versus A. baumannii ATCC
17978, determined using one-way ANOVA with Bonferroni contrasts. n.s., not signiﬁcant.
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the induction of the anti-inﬂammatory cytokine interleukin-10 (IL-10). To investigate
whether the reduced levels of IL-10 triggered by the lpxO mutant could be responsible
for the increased inﬂammatory response activated by this mutant, we infected il10/
iBMDMs and assessed inﬂammatory responses. No differences were observed in the
levels of inﬂammatory cytokines induced by the wild type and lpxO mutant (Fig. 7B),
supporting the notion that the increased inﬂammation triggered by the lpxO mutant is
due to a decrease in the levels of the anti-inﬂammatory cytokine IL-10.
We next sought to determine the signaling pathway governing the production of
IL-10 in A. baumannii-infected macrophages. The transcriptional factor CREB controls
the expression of IL-10 (31), and MAPK p38 and ERK have been shown to cooperate in
IL-10 induction following infection (32). Since we have already shown that A. baumanii
induced the activation of p38 and ERK (Fig. 6D), we focused on investigating the
potential role of CREB to control IL-10 production in A. baumanii-infected cells. Sup-
pression of endogenous expression of CREB using CREB-speciﬁc short interfering RNA
(siRNA) led to a signiﬁcant decrease in the levels of il10 in macrophages infected with
the wild-type strain (Fig. 7C), indicating that CREB indeed does govern A. baumannii
induction of IL-10. Remarkably, immunoblot analysis revealed that the phosphorylation
of CREB was decreased in macrophages infected with the lpxO mutant, in sharp
contrast to that of cells infected with the wild type (Fig. 7D). Image analysis showed a
19 and 29% decrease in the phosphorylation of CREB 20 and 40 min postinfection with
the lpxO mutant compared to that triggered by the wild type. Complementation of the
lpxO mutant restored the phosphorylation of CREB to wild-type levels (Fig. 7D).
Altogether, these ﬁndings demonstrate that the 2-hydroxylation of A. baumannii
lipid A mediates the production of the anti-inﬂammatory cytokine IL-10 via the acti-
vation of CREB. IL-10, in turn, limits the production of inﬂammatory cytokines following
A. baumannii infection.
DISCUSSION
The work described in this study demonstrates that A. baumannii encodes a lipid A
hydroxylase, LpxO, which mediates the 2-hydroxylation of the laurate transferred by
LpxLAb. This study demonstrates that LpxO-mediated 2-hydroxylation of lipid A pro-
tects the pathogen from CAMPs, mediates resistance to phagocytosis, and limits the
activation of inﬂammatory responses by macrophages. Our ﬁndings also show that the
lpxO mutant is attenuated in the G. mellonella infection model and that it induces a
heightened antimicrobial response. Altogether, this evidence supports that LpxO is a
bona ﬁde immune evasion factor of A. baumannii.
Few Gram-negative bacteria are known to produce lipid A containing hydroxylated
fatty acids, including pathogens such as Salmonella, Klebsiella, Bordetella, Pseudomonas,
Legionella, and V. cholerae (14–17, 33–35), and also environmental bacteria such as
Marinomonas and symbionts such as Vibrio ﬁscheri (36–38). Mechanistically, lipid A
hydroxylation is achieved either by the hydroxylation of fatty acids by the hydrolase
catalyzed by LpxO (15, 16) or by transfer of a hydroxylated fatty acid by the acyl
transferase LpxN (14). A. baumannii encodes an LpxO homolog which hydroxylates the
laurate linked to the 2= R-3-hydroxymyristoyl position of lipid A. Although our results
and those of Boll et al. (7) conclusively demonstrate the function of A. baumannii LpxO,
there is diversity on the lipid A position and fatty acid modiﬁed by other LpxO
homologs. K. pneumoniae LpxO hydroxylates the myristate linked to the same position
(16), whereas Salmonella LpxO hydroxylates the myristate linked to the 3= R-3-
hydroxymyristoyl position (15). The fact that lipid A hydroxylation seems to play a
conserved role counteracting immune defenses independently of how it is achieved
strongly suggests that incorporation of the hydroxyl group to lipid A is of the utmost
importance here.
Our results clearly show that the 2-hydroxylation of lipid A is another of the
mechanisms of A. baumannii to avoid the action of CAMPs and polymyxins. Of note, the
hydroxylation of lipid A also mediates resistance to CAMPs in Klebsiella and V. cholerae
(14, 16, 29), suggesting that this is an evolutionarily conserved mechanism of resistance
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against these antimicrobial agents. The fact that A. baumannii lipid A is constitutively
hydroxylated supports the notion that LpxO-mediated lipid A modiﬁcation can be
considered part of the intrinsic resistome of this pathogen against these antimicrobials.
Likewise, LpxM-dependent hepta-acylation of lipid A is also part of the A. baumannii
intrinsic resistome (7). In contrast, the modiﬁcation of A. baumannii lipid A with
phosphoethanolamine and galactosamine is an inducible mechanism of resistance so
far only found in clinical isolates as a result of colistin treatment (9–11). Future studies
are warranted to assess the relative contribution of these mechanisms to counteract
antimicrobial peptides and polymyxins. An extreme mechanism of inducible resistance
is the loss of LOS due to mutations in lipid A biosynthetic genes (12). However, these
strains increase the expression of other OM molecules, polysaccharides, and transport-
ers, which may also play a role in the resistance to CAMPs (13, 39).
Another novel ﬁnding of this study is that LpxO-mediated lipid A hydroxylation
attenuates the activation of defense responses. In G. mellonella, infection with the lpxO
mutants triggered an upregulation of the expression of CAMPs, whereas in macro-
phages the lpxO mutant elicited a heightened inﬂammatory response. These results
reinforce the notion that G. mellonella is a suitable surrogate infection model to assess
the activation of early innate immune responses. The ﬁndings of this work are consis-
tent with our earlier studies investigating K. pneumoniae LpxO-mediated lipid A mod-
iﬁcation (29, 30, 40), suggesting that the presence of a hydroxyl group on a lipid A
secondary acyl chain is a conserved microbial immune evasion mechanism.
TLR4 signaling is essential for initiating inﬂammatory responses in vitro and in vivo
to clear Acinetobacter infections (8, 41). Therefore, it is tempting to conclude that
2-hydroxylation of A. baumannii lipid A limits recognition by TLR4. However, our data
showed that LpxO-mediated hydroxylation contributes to the expression of IL-10 in
macrophages following infection. The fact that no differences were found in the
immune responses activated by the wild type and lpxOmutant in il10/macrophages
strongly suggests that there are no differences in the recognition of LPS with or without
hydroxylation. Collectively, this evidence is consistent with the notion that A. baumannii
LpxO-mediated lipid A modiﬁcation is an immune evasion mechanism dependent on
the production of the anti-inﬂammatory cytokine IL-10. Providing additional support to
this notion, the activation of the transcriptional factor CREB, necessary for the expres-
sion of IL-10 in macrophages (32), is signiﬁcantly reduced in macrophages infected with
the lpxO mutant. It is exciting to speculate that the induction of anti-inﬂammatory
responses upon recognition of hydroxylated lipid A is an evolutionarily conserved
mechanism to blunt immune responses. Future studies investigating other Gram-
negative pathogens synthesizing hydroxylated lipid A are required to validate this
hypothesis.
The World Health Organization has recently included A. baumannii in the list of
pathogens for which new therapeutics are urgently needed. Acinetobacter infections
are particularly troublesome within the health care setting and intensive care unit due
to the organism’s ability to resist disinfectants and to develop antibiotic resistance. The
emergence of even pan-drug-resistant strains emphasizes the urgent need of devel-
oping alternative therapeutics. Among other possibilities and based on the results of
this work, we put forward the idea that antivirulence therapeutics should be considered
a viable option. Compounds directed to block LpxO may render A. baumannii suscep-
tible to host CAMPs and may limit the attenuation of inﬂammatory responses. Inter-
estingly, this approach might be useful to treat other infections caused by other
multidrug-resistant pathogens producing hydroxylated lipid A, including Pseudomonas
and Klebsiella.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All strains and plasmids used in this study are listed in
Table 1. Strains were grown on lysogeny broth (LB) agar from frozen glycerol stocks at 37°C. Isolated
colonies were used to inoculate LB broth at 37°C on an orbital shaker (180 rpm). When indicated,
antibiotics were used at the following concentrations: carbenicillin (Carb), 50 g/ml; kanamycin (Km),
25 g/ml; chloramphenicol (Cm), 10 g/ml; trimethoprim (Tp), 100 g/ml; tetracycline (Tet), 12.5 g/ml.
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To assess growth of A. baumannii strains, bacteria were grown as stated previously, and 5 l of this
culture was used to inoculate 250 l of fresh LB. Absorbance readings of the optical density at 600 nm
(OD600) were measured and recorded over a 24-h period with readings at 20-min intervals using a
Bioscreen C automated microbial growth analyzer (MTX Lab Systems, Vienna, VA, USA). A total of 10
independent growth curves were obtained per strain.
A. baumannii mutant construction. Primers for mutant construction (see Table S1 in the supple-
mental material) were designed using the whole-genome sequence of A. baumannii ATCC 17978
(GenBank accession no. CP000521.1). The primer pairs lpxO_UPFWD, lpxO-UPRVS, lpxO_DOWNFWD, and
lpxO_DOWNRVS (Table S1) were used in two separate PCRs to amplify fragments ﬂanking A1S_0308 (A.
baumannii lpxO) using Ex Taq polymerase (TaKaRa). Each amplicon had internal BamHI restriction sites
added internally to the ﬂanking regions. Gel-extracted lpxO UP and DOWN fragments were polymerized
and ampliﬁed to generate a single PCR amplicon of the lpxO gene using primers lpxO_UPFWD and
lpxO_DOWNRVS. This 1,655-bp amplicon was cloned into pGEM-T Easy (Promega) to obtain pGEMΔlpxO
and transformed into E. coli C600 cells. After EcoRI digestion, the 1,655-bp amplicon was gel puriﬁed,
cloned into EcoRI-digested Antarctic Phosphatase (New England Biolabs)-treated pGPI-SceI-2 suicide
vector (42) to obtain pGPI-SceI-2ΔlpxO, and transformed into E. coli GT115 cells. pGPI-SceI-2ΔlpxO was
transformed into E. coli 2163 (43), a diaminopimelate (DAP) auxotrophic donor strain with conjugative
pili. pGPI-SceI-2ΔlpxO was mobilized into A. baumannii by conjugation. The cointegrant clones were
selected using LB agar supplemented with Tp at 37°C. A second crossover event was performed by
conjugating the pDAI-SceI-SacB plasmid (42) into an overnight culture grown to mid-exponential phase
containing up to three Tp-resistant cointegrant clones. Exconjugants were selected with LB agar
containing Tet at 37°C. Candidate clone colonies were screened for susceptibility to Tp on LB agar
supplemented with Tp. Additionally, colony PCRs were performed using the lpxO_ UPFWD and lpx-
O_DOWNRVS primers. sacB allows curing of the pDAI-SceI-SacB vector by passaging the Tet-resistant,
Tp-sensitive, PCR-conﬁrmed colonies onto 6% sucrose LB agar without NaCl for 24 h at 30°C. The
resulting colonies were screened for susceptibility to both Tet and Tp and conﬁrmed with the afore-
mentioned primers. This mutant was named the A. baumannii ΔlpxO mutant.
Complementation of A. baumannii lpxO mutant. To complement the A. baumannii ΔlpxO mutant,
a DNA fragment comprising the coding and promoter regions of lpxO was ampliﬁed using Phusion
high-ﬁdelity DNA polymerase (New England Biolabs) and primers Ab_lpxO_UP_F1 and Ab_lpxO_
DWN_R1 (Table S1). The amplicon was gel extracted and cloned into ScaI-digested (New England
Biolabs), Antarctic Phosphatase-treated pUC18R6KT-mini-Tn7Km plasmid (44) to generate pUC18R6KT-
mini-Tn7Km_17978lpxOCom. The resulting plasmid was then transformed into E. coli GT115 and subse-
quently into E. coli 2163. The transposase-containing pTNS2 and pUC18R6KT-mini-
Tn7Km_17978lpxOCom were mobilized into the A. baumannii ΔlpxO mutant by triparental conjugation
and, once recovered on LB DAP agar, were serially diluted on LB Km agar; the pTNS2-thermosensitive
helper plasmid was cured by incubating for 6 h at 42°C, followed by overnight incubation at 37°C.
TABLE 1 Strains and plasmids used in this study
Bacterial strain or plasmid Genotype or comment(s) Source or reference
Strains
A. baumannii
ATCC 17978 Wild-type strain American Type
Culture Collection
ATCC 17978-ΔlpxO ATCC 17978 with the lpxO gene inactivated This study
ATCC 17978-ΔlpxO::Tn7lpxO ATCC 17978, ΔlpxO; Tn7Km_17978lpxOCom integrated into attTn7
site, Kmr
This study
E. coli
C600 thi thr leuB tonA lacY supE Laboratory collection
GT115 F mcrA Δ(mrr-hsdRMS-mcrBC) 80lacZΔM15 ΔlacX74 recA1 rpsL (strA)
endA1 dcm uidA(ΔmluI)::pir-116 sbcC-sbcD
InvivoGen
2163 F RP4-2-Tc::Mu-d dapA::(erm-pir), Kmr, Emr 43
MG1655 F  ilvG rfb-50 rph-1 Laboratory collection
BN1 W3110 ΔeptA ΔlpxT ΔpagP 19
BN1 ΔlpxL BN1 ΔlpxL::FRT; the lpxL gene was inactivated 40
BN1 ΔlpxL::Tn7lpxO BN1 ΔlpxL::FRT; Tn7Km_17978lpxOCom integrated into attTn7 site, Kmr This study
Plasmids
pGEM-T Easy Cloning plasmid, Ampr Promega
pGPI-SceI-2 Suicide vector, R6Kgamma origin of replicaion, Mob, carries an I-SceI
endonuclease site, Tpr
42
pDAI-SceI-SacB Expresses the I-SceI endonuclease gene, sacB, Tetr 42
pTNS2 T7 transposase expression vector, oriR6K, Ampr 49
pUC18R6kT-mini-Tn7TKm pUC18R6KT-mini-Tn7TKm complementation vector, Ampr, Kmr 44
pGEMΔlpxO pGEM-T Easy containing ΔlpxO; Ampr This study
pGPI-SceiI-2ΔlpxO pGPI-SceI-2 containing ΔlpxO, Tpr This study
pUC18R6kT-mini-Tn7TKm-17978lpxO pUC18R6kT-mini-Tn7TKm containing lpxO gene for complementation,
Ampr, Kmr
This study
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Candidate colonies were screened for sensitivity to Tp. Correct integration of the Tn7 transposon was
conﬁrmed by PCR using the primers Tn7-R and glmSF1. The presence of lpxO was conﬁrmed by PCR
using the primers lpxO_UPFWD and lpxO_DOWNRVS. This strain was named the A. baumannii ΔlpxO::
Tn7lpxO mutant.
pUC18R6KT-mini-Tn7Km_17978lpxOCom was also conjugated into E. coli BN1 and the BN1 ΔlpxL
mutant as we have previously described (40).
Lipid extraction and analysis. Total lipids were extracted as described by Bligh and Dyer (45) and
analyzed on silica gel 60 high-performance thin-layer chromatography (HPTLC) plates (Merck, Darmstadt,
Germany). The plates were prewashed by solvent migration with a chloroform-methanol-acetic acid
mixture (13:5:2) and dried thoroughly, samples were applied to the plate, and chromatography was
performed in the same mixture of solvents. Plates were developed by charring with 15% sulfuric acid in
ethanol at 180°C. Spots corresponding to lipids were quantiﬁed by densitometry using a GS-800
calibrated densitometer and Quantity One software (Bio-Rad).
Fluorimetry. The ﬂuorescent probe N-phenyl-1-naphthylamine (NPN) (Sigma) has been used in outer
membrane permeability studies. Fluorimetric assays were carried out as described by Martínez de Tejada
et al. (46), with minor modiﬁcations. Exponentially growing bacteria were resuspended in 1 mM KCN–
10 mM HEPES (pH 7.2) at an optical density at 600 nm of 0.1 and transferred to ﬂuorimetric cuvettes.
Fluorescence was monitored with an FLS920 Edinburgh ﬂuorimeter with the following settings: excita-
tion wavelength, 350 nm; emission wavelength, 420 nm; slit width, 5.0 nm. The results were expressed in
relative ﬂuorescence units.
Lipid A extraction. Lipid A was extracted using an isobutyric acid-ammonium hydroxide method
(47) and analyzed with negative-ion MALDI-TOF mass spectrometry. Brieﬂy, 10 ml of bacteria was grown
to mid-exponential phase and washed three times with equal volumes of 10 mM phosphate buffer. The
pellet was washed twice in 400 l of chloroform-methanol (1:2 [vol/vol]) in a screw-cap test tube and
centrifuged (2,000 g for 15 min); the resulting pellet was resuspended in 400 l of chloroform-
methanol-water (3:2:0.25 [vol/vol/vol]) and centrifuged (2,000 g for 15 min). The pellet was treated
with 400 l of isobutyric acid–1 M ammonium hydroxide (5:3 [vol/vol]) and incubated for 2 h at 100°C
with occasional vortexing to hydrolyze the 3-deoxy-D-manno-octulosonic acid bond. The lipid A suspen-
sions were then cooled in ice water and centrifuged (2,000 g for 15 min), and the supernatant was
transferred to a fresh screw-cap tube with an equal volume of deionized, sterile water and lyophilized.
The lyophilized material was washed twice with 400 l of absolute methanol and centrifuged (2,000 g
for 15 min). Lipid A was solubilized in 60 to 100 l of chloroform-methanol-water (3:1.5:0.25 [vol/vol/vol]).
A small volume of the solubilized lipid A was transferred to fresh 1.5-ml microcentrifuge tubes, desalted
with a few grains of ion exchange resin (H; Dowex 50W-X8), and brieﬂy centrifuged. A 1-l aliquot was
deposited on a polished steel target plate for the dried droplet method. An equal volume of 2,5-
dihydroxybenzoic acid (2,5-DHB) matrix (Bruker Daltonics, Inc.) was saturated in 100 mM citric acid
(Sigma-Aldrich) or acetonitrile–0.1% triﬂuoroacetic acid (1:2 [vol/vol]) and allowed to air dry. Lipid A
structural spectra were generated with a Bruker Autoﬂex Speed TOF/TOF mass spectrometer (Bruker
Daltons Inc.) in negative reﬂectron mode with delayed extraction. All spectra were achieved with
ion-accelerating voltage set at 20 kV, and resulting spectra were generated with an average of 300 shots.
A peptide calibration standard (Bruker Daltonics, Inc.) was used to calibrate the MALDI-TOF mass
spectrometer prior to analysis of each sample. Lyophilized E. coli MG1655 lipid A grown in LB broth at
37°C with identical extraction was used as an internal calibrant. Spectra are representative of at least
three independent lipid A extractions.
CAMP susceptibility assays. To assess A. baumannii susceptibility to CAMPs, we performed a
modiﬁed version of the sensitivity assay described by Llobet and coworkers (48). Each strain was grown
to mid-exponential phase in LB broth, washed once with PBS, and diluted in liquid test medium
composed of 1% tryptone soy broth (Oxoid), 10 mM phosphate buffer (pH 6.5), 100 mM sodium chloride
(Sigma-Aldrich) to approximately 3 104 CFU/ml. Aliquots (25 l) of each strain were then mixed with
5 l of either PBS or PBS containing antimicrobial peptides in 0.2-ml tubes. After 1 h of incubation at
37°C, 15 l of the suspension was spread onto LB agar and incubated overnight at 37°C. Percent survival
of the bacterial strains exposed to the antimicrobial peptides was calculated through comparison with
the unexposed PBS controls. All assays were performed in duplicate on three independent experiments.
Whole-blood phagocytosis assay. Bacteria were grown at 37°C in 5 ml of LB broth on an orbital
shaker (180 rpm) until mid-exponential phase and then harvested (3,000 g, 15 min). Bacteria were
washed once with sterile PBS and adjusted to an OD600 of 1.00. Three hundred microliters of fresh human
blood (used within 30 min of collection with 10% citrate dextrose as an anticoagulant) was mixed with
1 107 CFU/100 l bacterial suspension and incubated on an orbital shaker at 37°C (180 rpm) for 3 h.
Following incubation, serial dilutions were performed in sterile PBS and spread on LB agar. Bacterial
counts recovered were then divided by the initial counts. Experiments were performed using blood from
three individual donors, and for each blood sample the strains were tested in duplicate. Donors were all
adult males, with no existing medical conditions or infections; none of the donors had used any
anti-inﬂammatory medication for at least 24 h prior to blood withdrawal. Ethical approval for the use of
blood from healthy volunteers to study bacterial killing was obtained from the Research Ethics Com-
mittee of the School of Medicine, Dentistry, and Biomedical Sciences (Queen’s Univeristy, Belfast, Ireland).
Infection of G. mellonella larvae. G. mellonella larvae were obtained from UK Waxworm Limited and
stored at 12°C in the dark without dietary supplementation. All experiments were performed within
7 days of receipt, comprising randomly selected larvae with a healthy, nonmelanized appearance and
within a weight range of 250 to 350 mg.
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Infections were performed as described previously, with minor modiﬁcations (30). Brieﬂy, bacteria were
grown in 5ml LB broth until mid-exponential phase (37°C, 180 rpm) and centrifuged (3,000 g, 15min),
washed once with sterile PBS, and adjusted to 5 106 CFU/ml. Larvae were surface disinfected with 70%
(vol/vol) ethanol and then injected with 10l of the bacterial suspension, containing 5 104 CFU, in the rear
right proleg with a Hamilton syringe with a 27-gauge needle. A group of 10 larvae was also injected with 10l
of sterile PBS to ensure death was not due to mechanical trauma. Larvae were placed in a 9.2-cm petri dish,
kept at 37°C in the dark, and monitored every 24 h. Galleria organisms were considered dead when they were
unresponsive to physical stimuli. Larvae were examined for pigmentation, and time of death was recorded.
Pupa formation was observed among control larvae after 3 days, and experiments were ceased from this time
point. The virulence assay was performed in triplicate (30 larvae total per strain).
G. mellonella RNA extraction and RT-qPCR. Larvae were infected with  5 104 CFU of the three
A. baumannii strains, incubated at 37°C for 12 h, and homogenized in 1 ml TRIzol reagent (Ambion) using
a VDI 12 tissue homogenizer (VWR). Total RNA was extracted according to the manufacturer’s guidelines.
Further puriﬁcation was achieved by treating 1 g of RNA with DNase I (Thermo Scientiﬁc) at 37°C for
30 min and then 65°C for 10 min in the presence of 50 mM EDTA. RNA was quantiﬁed using a Nanovue
Plus spectrophotometer (GE Healthcare Life Sciences). cDNA was generated by retrotranscription of 1 g
of total RNA using Moloney murine leukemia virus (M-MLV) reverse transcriptase (Invitrogen) and
random primers (Invitrogen). Ten nanograms of cDNA was used as the template in a 5-l reaction
mixture from a KAPA SYBR FAST quantitative PCR (qPCR) kit (Kapa Biosystems) and target primer mix
(Table S1). Reverse transcription-qPCR (RT-qPCR) was performed using a Rotor-Gene Q (Qiagen) with the
following thermocycling conditions: 95°C for 3 min for hot-start polymerase activation, followed by 40
cycles of 95°C for 5 s and 60°C for 20 s. Fluorescence of SYBR green dye was measured at 510 nm. Relative
quantities of mRNAs were obtained using the comparative threshold cycle (ΔΔCT) method by normal-
ization to the amount of 18S rRNA.
G. mellonella hemolymph microbroth assay. Larvae were infected with 1 106 heat-killed (65°C
for 20 min) E. coliMG1655 organisms to prime the antimicrobial factors in the hemolymph and incubated
at 37°C for 24 h. Hemolymphs from ten larvae were pooled in an ice-cold microcentrifuge tube
containing 10 l of 1 mg/ml N-phenylthiourea (Sigma). Five microliters of the hemolymph suspension
was then used in the antimicrobial peptide assay previously described.
Generation of iBMDM-derived macrophages. To isolate BMDMs (bone marrow-derived macro-
phages), tibias and femurs from C57BL/6 or IL-10/ mice (C57BL/6 background) were removed using
sterile techniques, and the bone marrow was ﬂushed with fresh medium. To obtain macrophages, cells
were plated in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with 20% ﬁltered L929 cell
supernatant (a source of macrophage colony-stimulating factor) and maintained at 37°C in a humidiﬁed
atmosphere of 5% CO2. Medium was replaced with fresh supplemental medium after 1 day. After 5 days,
BMDMs were immortalized by exposing them for 24 h to the J2 CRE virus (carrying v-myc and v-Raf/v-Mil
oncogenes, kindly donated by Avinash R. Shenoy, Imperial College London). This step was repeated
2 days later (day 7), followed by continuous culture in DMEM supplemented with 20% (vol/vol) ﬁltered
L929 cell supernatant for 4 to 6 weeks. The presence of a homogeneous population of macrophages was
accessed by ﬂow cytometry using antibodies for CD11b (clone M1/70; catalog number 17-0112-82;
eBioscience) and CD11c (clone N418; catalog number 48-0114-82; eBioscience).
Macrophage infections. iBMDMs (cell line derived from wild-type NR9456 mice; BEI Resources,
NIAID, NIH) were grown in DMEM (catalog number 41965; Gibco) supplemented with heat-inactivated
fetal calf serum, 100 U/ml penicillin, and 0.1 mg/ml streptomycin (Gibco) at 37°C in a humidiﬁed 5% CO2
incubator. Cells were routinely tested for Mycoplasma contamination. For infections, iBMDMs were
seeded to a density of 2.5 104/well in 96-well plates, 5 105/well in 12-well plates, and 1 106/well
in 6-well plates.
Bacteria were grown in 5 ml LB broth until mid-exponential phase at 37°C on an orbital shaker
(180 rpm), recovered by centrifugation (3,000 g, 15 min), and adjusted to an OD600 of 1.00 in sterile PBS
corresponding to 1.2 108 CFU/ml. Bacterial suspensions were serially diluted in PBS to count input
of the bacteria and then UV irradiated at 15 J for 30 min, with conﬁrmation of bacterial cell death by
plating on LB agar. Infections were performed at a multiplicity of infection (MOI) of 20 bacteria per
iBMDM. Synchronization of the infection was performed by centrifugation (200 g for 5 min). All
infections were performed in duplicate and repeated three independent times.
Macrophage RNA isolation and RT-qPCR. Infections were performed in 6-well plates with UV-killed
A. baumannii for 5 h. Cells were washed three times with prewarmed sterile PBS, and total RNA was
extracted from the cells in 1 ml of TRIzol reagent (Ambion) according to the manufacturer’s instructions.
Extracted RNA was treated with DNase I (Roche) and precipitated with sodium acetate (Ambion) and
ethanol. RNA was quantiﬁed using a Nanovue Plus spectrophotometer (GE Healthcare Life Sciences).
cDNA was generated by retrotranscription of 1 g of total RNA using M-MLV reverse transcriptase
(Invitrogen) and random primers (Invitrogen). Ten nanograms of cDNA was used as a template in a 5-l
reaction mixture from a KAPA SYBR FAST qPCR kit (Kapa Biosystems) and target primer mix (Table S1).
RT-qPCR was performed using a Rotor-Gene Q (Qiagen) with the following thermocycling conditions:
95°C for 3 min for hot-start polymerase activation, followed by 40 cycles of 95°C for 5 s and 60°C for 20 s.
Fluorescence of SYBR green dye was measured at 510 nm. Relative quantities of mRNAs were obtained
using the ΔΔCT method by using hypoxanthine phosphoribosyltransferase 1 (hprt) gene normalization.
Transfection conditions. For transfection of siRNAs, 1 106 iBMDMs (6-well format) were trans-
fected in suspension with 20 nM siRNA using Lipofectamine and Opti-MEM I (ThermoFisher) in a ﬁnal
volume of 2 ml. AllStars negative-control siRNA (Qiagen) or ON-TARGETplus SMARTpool siRNA targeting
CREB1 (no. L-040959-01; Dharmacon) was used to transfect cells for 16 h. Cells then were mock infected
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with PBS or infected with UV-killed A. baumannii ATCC 17978 as described previously. RNA was collected
and RT-qPCR analyses were performed as previously described. Knockdown efﬁciency (Fig. S4) was
determined using primers for creb (Table S1).
Immunoblots. Proteins were resolved on standard 10% SDS-PAGE gels and electroblotted in a
semidry manner onto nitrocellulose membranes. Membranes were subsequently blocked with 3%
(wt/vol) bovine serum albumin in TBS-Tween (TBST), and speciﬁc antibodies were used to detect protein
using chemiluminescence reagents and a G:BOX Chemi XRQ chemiluminescence imager (Syngene).
All antibodies were probed with a secondary goat anti-rabbit/mouse antibody conjugated to IgG
horseradish peroxidase, diluted 1:5,000 (no. 170-6515/170-6516; Bio-Rad). Antibodies used in this study
were anti-IB (anti-rabbit, 1:1,000; no. 4812S; Cell Signaling), anti-phospho-JNK (anti-rabbit, 1:1,000; no.
9251S; Cell Signaling), anti-phospho-ERK (anti-rabbit, 1:1,000; no. 9101; Cell Signaling), anti-phospho-
CREB (anti-rabbit, 1:1,000; no. sc-7978-R; Santa Cruz Biotechnology), and anti-phospho-p38 (anti-rabbit,
1:1,000; no. 4511; Cell Signaling). To ensure that equal amounts of proteins were loaded, blots were
reprobed with -tubulin (anti-mouse, 1:4,000; no. T5168; Sigma-Aldrich).
To detect multiple proteins, membranes were reprobed after stripping of previously used antibodies
using a pH 2.2 glycineHCl–SDS buffer.
Bands were analyzed using ImageJ with the Histogram analysis tool, and results were expressed as a
percentage of the intensity of the band found in the samples from cells infected with the wild-type strain.
Quantiﬁcation of cytokines. Infections were performed in 12-well plates (5 105 cells per well) at
an MOI of 20:1 UV-killed bacteria. After 5 h of infection, supernatants were collected and spun down at
12,000 g for 5 min to remove any debris. TNF- in the supernatants was determined using a murine
TNF- standard TMB enzyme-linked immunosorbent assay development kit (no. 900-T54; PeproTech)
according to the manufacturer’s instructions. All experiments were performed in duplicate, and three
independent experiments were conducted.
Statistical analysis. Statistical analyses were performed using one-way analysis of variance (ANOVA)
with Bonferroni corrections, the one-tailed t test, or, when the requirements were not met, the
Mann-Whitney U test. P values of 0.05 were considered statistically signiﬁcant. Normality and equal
variance assumptions were tested with the Kolmogorov-Smirnov test and the Brown-Forsythe test,
respectively. Survival analyses were undertaken using the logrank (Mantel-Cox) test with Bonferroni
correction for multiple comparisons ( 	 0.008). All analyses were performed using GraphPad Prism for
Windows (version 6.01) software.
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